Invesco Portfolio holdings
Invesco Ltd., founded in 1978 and headquartered in Atlanta, Georgia, is a global investment management firm managing hundreds of billions in assets across a diverse range of products, including mutual funds, exchange-traded funds (ETFs), and institutional portfolios. Known for its blend of active and passive investment strategies, Invesco serves individual investors, financial advisors, and institutions, with a strong presence in North America, Europe, and Asia, bolstered by acquisitions like OppenheimerFunds in 2019. The firm offers specialized solutions in equities, fixed income, real estate, and alternatives, leveraging its global research capabilities to cater to varying market needs. Invesco’s commitment to innovation and client-focused investing has solidified its reputation as a versatile player in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HEICO Corp Class A
HEI.A
|
+$873M |
| 2 |
Ferguson
FERG
|
+$750M |
| 3 |
UnitedHealth
UNH
|
+$641M |
| 4 |
Apple
AAPL
|
+$619M |
| 5 |
Visa
V
|
+$612M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vale
VALE
|
+$814M |
| 2 |
Pinduoduo
PDD
|
+$699M |
| 3 |
Meta Platforms (Facebook)
META
|
+$470M |
| 4 |
Home Depot
HD
|
+$382M |
| 5 |
Mid-America Apartment Communities
MAA
|
+$369M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.91% |
| 2 | Financials | 13.06% |
| 3 | Healthcare | 12.67% |
| 4 | Consumer Discretionary | 10.55% |
| 5 | Industrials | 10.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKTS
3726
DELISTED
Akoustis Technologies Inc
AKTS
| $125K | ﹤0.01% |
19,326
+1,167
| +6% | +$6.94K |
|
3727
Cullinan Oncology
CGEM
$1.06B
| $124K | ﹤0.01% |
11,834
+203
| +2% | +$2.74K |
|
3728
Oramed Pharmaceuticals
ORMP
$162M
| $124K | ﹤0.01% |
14,370
+1,379
| +11% | +$14.1K |
|
|
GTHX
3729
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $122K | ﹤0.01% |
16,108
-8,561
| -35% | -$81.2K |
|
|
CELL
3730
DELISTED
PhenomeX Inc. Common Stock
CELL
| $122K | ﹤0.01% |
17,174
-2,784,004
| -99% | -$23M |
|
|
MRSN
3731
DELISTED
Mersana Therapeutics
MRSN
| $120K | ﹤0.01% |
1,203
+14
| +1% | +$1.64K |
|
3732
VEON
VEON
$3.5B
| $119K | ﹤0.01% |
6,987
-12,516
| -64% | -$340K |
|
|
DIDI
3733
DELISTED
DiDi Global Inc. American depositary shares, each four representing one Class A ordinary share
DIDI
| $117K | ﹤0.01% |
47,074
-22,727,029
| -100% | -$89.7M |
|
3734
Personalis
PSNL
$1.25B
| $116K | ﹤0.01% |
14,140
+95
| +0.7% | +$984 |
|
|
RUBY
3735
DELISTED
Rubius Therapeutics, Inc
RUBY
| $116K | ﹤0.01% |
21,047
+377
| +2% | +$2.39K |
|
3736
Kiniksa Pharmaceuticals
KNSA
$6.31B
| $113K | ﹤0.01% |
11,396
+156
| +1% | +$1.65K |
|
|
GPUS
3737
Hyperscale Data Inc
GPUS
$52.9M
| $113K | ﹤0.01% |
1
| – | – |
|
3738
Dyne Therapeutics
DYN
$4.68B
| $112K | ﹤0.01% |
11,698
+292
| +3% | +$2.49K |
|
3739
Caribou Biosciences
CRBU
$146M
| $110K | ﹤0.01% |
+12,113
| New | +$128K |
|
3740
NexGen Energy
NXE
$5.91B
| $108K | ﹤0.01% |
19,167
-13,706
| -42% | -$65.8K |
|
3741
Rimini Street
RMNI
$457M
| $106K | ﹤0.01% |
18,170
-158
| -0.9% | -$830 |
|
3742
Farmmi Inc
FAMI
$5.61M
| $103K | ﹤0.01% |
+285
| New | +$130K |
|
3743
Immunovant
IMVT
$7.93B
| $103K | ﹤0.01% |
18,700
+711
| +4% | +$4.43K |
|
3744
Standard BioTools
LAB
$342M
| $103K | ﹤0.01% |
28,600
-43,023
| -60% | -$149K |
|
|
CLVS
3745
DELISTED
Clovis Oncology, Inc.
CLVS
| $101K | ﹤0.01% |
49,947
+704
| +1% | +$1.38K |
|
|
URG
3746
Ur-Energy
URG
$469M
| $100K | ﹤0.01% |
62,451
+862
| +1% | +$1.22K |
|
|
KLRS
3747
Kalaris Therapeutics
KLRS
$80.9M
| $99K | ﹤0.01% |
636
+5
| +0.8% | +$997 |
|
|
GTH
3748
DELISTED
Genetron Holdings Limited ADS
GTH
| $99K | ﹤0.01% |
15,008
+6,947
| +86% | +$76.1K |
|
3749
Absci
ABSI
$1.17B
| $96K | ﹤0.01% |
+11,460
| New | +$90K |
|
3750
Precigen
PGEN
$1.94B
| $93K | ﹤0.01% |
44,573
+921
| +2% | +$2.24K |
|
Similar funds
Invesco's Q1 2022 Portfolio in Review
As of Q1 2022, Invesco held 4,189 positions worth $392B, down 5.5% from $415B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Invesco's Q1 2022 filing shows 137 new, 2,071 increased, 1,612 reduced and 191 closed positions. Its largest new stake was Ferguson: 4,859,882 shares worth $652M. The largest sale was Vale, an estimated $814M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Financials and Healthcare.
- Invesco's largest Q1 2022 buy was Ferguson: 4,859,882 shares worth $652M.
- Invesco added most to HEICO Corp Class A in Q1 2022, an estimated $873M increase.
- Invesco's biggest Q1 2022 reduction was Vale, cutting an estimated $814M.
- Invesco fully exited Xilinx Inc in Q1 2022, selling an estimated $200M.
- Invesco's ten largest holdings make up 12% of its $392B portfolio in Q1 2022.
- Invesco opened 137 new positions and closed 191 in Q1 2022.
- Invesco's portfolio value fell 5.5% quarter-over-quarter to $392B.
Based on Invesco's 13F filing for Q1 2022, filed 16 May 2022.